Cochrane Stories is a new series of special sessions created for the Vienna Colloquium. Cochrane stories are not scientific presentations of numbers and facts but rather personal stories of struggles, challenges, successes, and maybe failures.
Based on incomplete evidence, governments around the world have spent billions of dollars stockpiling neuraminidase inhibitors (NI) such as Tamiflu® and Relenza® in anticipation of an influenza pandemic. The Cochrane NI Research Group has reviewed more than 160,000 pages of regulatory documents in order to examine the full evidence picture. In this session, you will hear the story behind the Neurominidase Inhibitors Review and its implications.

Chairs: TBA

Speakers:
Carl Heneghan, Co-Author of 2014 Cochrane Review on neuraminidase inhibitors
"The fight to get access to the Tamiflu data"

Tom Jefferson, Lead author of 2014 Cochrane Review on neuraminidase inhibitors
"Why were the regulatory data vital to anser the question and the aftermath - what does this mean for Cochrane and for health decision making?"